A multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 2a trial to evaluate the efficacy and safety of BP1.4979 in adult participants with obsessive compulsive disorder

Condition studied

Obsessive compulsive disorder

Investigational medicinal product(s)

Eligibility

Primary endpoint

The primary efficacy endpoint is the change in the total score on the Yale-Brown ObsessiveCompulsive Scale Second Edition (YBOCS-II) at end of treatment.

Endpoint detail

Change in total score of the YBOCS-II at visits 3 and 4, Change in total score of Obsessive-Compulsive Inventory-Revised (OCI-R) at visits 3, 4 and 5, Change in global functioning responses as assessed on the Clinical Global Impressions – Change (CGI-C) scale, Change in total score of Montgomery and Asberg Depression rating scale (MADRS)